A5061527020- Biosensors and Analytical Detection
- SARS-CoV-2 detection and testing
- Molecular Biology Techniques and Applications
- Advanced biosensing and bioanalysis techniques
- Cancer Genomics and Diagnostics
- SARS-CoV-2 and COVID-19 Research
- Gene expression and cancer classification
- Helminth infection and control
- Single-cell and spatial transcriptomics
- Coccidia and coccidiosis research
- Epigenetics and DNA Methylation
- Respiratory viral infections research
- COVID-19 diagnosis using AI
- Congenital heart defects research
Intellectual Ventures (United States)
2020-2021
Bellevue Hospital Center
2020-2021
University of Washington
2021
Allen Institute
2016
Allen Institute for Brain Science
2016
The rapid onset of the global COVID-19 pandemic has led to challenges for accurately diagnosing disease, including supply shortages sample collection, preservation, and purification. Currently, most diagnostic tests require RNA extraction detection by RT-PCR; however, is expensive time-consuming requires technical expertise. With these in mind, we report extraction-free, multiplexed amplification SARS-CoV-2 from 246 clinical samples, resulting 86% sensitivity 100% specificity. multiplex...
A unique four-plexed RT-LAMP test kit operated by health workers can provide faster, more sensitive results than laboratory tests.
The global COVID-19 pandemic has created an urgent demand for large numbers of inexpensive, accurate, rapid, point-of-care diagnostic tests. Analyte-based assays are suitably rapid and inexpensive can be rapidly mass-produced, but sufficiently accurate performance, they require highly optimized antibodies assay conditions. We used automated liquid handling system, customized to handle arrays lateral flow (immuno)assays (LFAs) in a high-throughput screen, identify anti-nucleocapsid that will...
Metagenomic sequencing of microbial cell-free DNA (cfDNA) in blood and urine is increasingly used as a tool for unbiased infection screening. The sensitivity metagenomic cfDNA assays determined by the efficiency which assay recovers vs host-specific cfDNA. We hypothesized that choice methods isolation, library preparation, would affect sequencing.
The global COVID-19 pandemic has created an urgent demand for large numbers of inexpensive, accurate, rapid, point-of-care diagnostic tests. Analyte-based assays are suitably inexpensive and can be rapidly mass-produced, but sufficiently accurate performance they require highly optimized antibodies assay conditions. We used automated liquid handling system, customized to handle arrays lateral flow immunoassay (LFA) tests in a high-throughput screen, identify anti-nucleocapsid that will...
The global COVID-19 pandemic has created an urgent demand for accurate rapid point of care diagnostic tests. Antigen-based assays are suitably inexpensive and can be rapidly mass-produced, but sufficiently performance requires highly-optimized antibodies assay conditions. An automated liquid handling system, customized to handle lateral flow immunoassay (LFA) arrays, was used high-throughput antibody screening anti-nucleocapsid that will perform optimally on LFA. Six hundred seventy-three...
The rapid onset of the global COVID-19 pandemic has led to multiple challenges for accurately diagnosing infection. One main bottlenecks detection is reagent and material shortages sample collection, preservation, purification prior testing. Currently, most authorized diagnostic tests require RNA extraction from patient samples by reverse transcription polymerase chain reaction (RT-PCR). However, expensive, time consuming, requires technical expertise perform. Additionally, there have been...
ABSTRACT RNA amplification tests allow sensitive detection of SARS-CoV-2 infection, but their complexity and cost are prohibitive for expanding COVID-19 testing. We developed “Harmony COVID-19”, a point-of-care test using inexpensive consumables, ready-to-use reagents, simple device that processes up to 4 samples simultaneously. Our lyophilized reverse-transcription, loop-mediated isothermal (RT-LAMP) can detect as little 15 copies per reaction, it report early 17 min with high viral load (2...
<p></p><p>The global COVID-19 pandemic has created an urgent demand for large numbers of inexpensive, accurate, rapid, point-of-care diagnostic tests. Analyte-based assays are suitably inexpensive and can be rapidly mass-produced, but sufficiently accurate performance they require highly optimized antibodies assay conditions. We used automated liquid handling system, customized to handle arrays lateral flow immunoassay (LFA) tests in a high-throughput screen, identify...